Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIC: Early CNS Prophylaxis in High Risk DLBCL
NCT01325194Phase 2Completed
- Sponsor
- Nordic Lymphoma Group
- Start
- Mar 2011
- Primary completion
- Nov 2018
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of liposomal cytarabine in diffuse large B-cell lymphoma (DLBCL), sponsored by Nordic Lymphoma Group. Primary endpoints: Time to treatment failure at 5 years and CNS relapse rate at 1.5 years. Started Mar 2011; status: completed.
02
Drugs
liposomal cytarabine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01325194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01325194.